Education
About Us
Working with TipRanks
Follow Us
GDOC - ETF AI Analysis
Top Page
Goldman Sachs Future Health Care Equity ETF (GDOC)
Rating:70Neutral
Price Target:―
Positive Factors
Strong Top Holdings
Several key holdings, such as AbbVie and Argenx, have shown strong year-to-date performance, contributing positively to the ETF's returns.
Focused Sector Exposure
The ETF's heavy allocation to the health care sector provides targeted exposure to a historically resilient and growing industry.
Solid Short-Term Performance
The ETF has delivered steady gains over the past month and quarter, indicating positive momentum in the near term.
Negative Factors
High Expense Ratio
The ETF charges a relatively high expense ratio, which could eat into long-term returns compared to lower-cost alternatives.
Sector Concentration Risk
With over 97% of assets in health care, the fund is highly exposed to risks specific to this sector.
Underperforming Holding
Intuitive Surgical has shown negative year-to-date performance, which could drag on overall returns if the trend continues.
GDOC vs. SPDR S&P 500 ETF (SPY)
AUM21.90M
RegionGlobal
Expense Ratio0.75%
Beta0.69
IssuerGoldman Sachs
Inception DateNov 09, 2021
Dividend Yield0.02%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume620
30 Day Avg. Volume972
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
40.90Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering39
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GDOC Summary
The Goldman Sachs Future Health Care Equity ETF (GDOC) focuses on the health care sector, specifically companies leading innovation in health care technology. This includes areas like telemedicine, biotech, and advanced medical devices. Some well-known companies in the ETF are Eli Lilly & Co and Boston Scientific. Investors might consider GDOC for its potential growth as health care continues to evolve with new technologies. However, it’s important to note that this ETF is heavily concentrated in the health care sector, meaning its performance could be impacted if the industry faces challenges.
How much will it cost me?The Goldman Sachs Future Health Care Equity ETF (GDOC) has an expense ratio of 0.75%, meaning you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on specialized health care technology companies that require more research and expertise to select.
What would affect this ETF?The Goldman Sachs Future Health Care Equity ETF (GDOC) could benefit from increasing demand for health care technology, driven by advancements in telemedicine, biotech, and medical devices, as well as global aging populations requiring innovative solutions. However, it may face challenges from regulatory changes in the health care sector, fluctuating interest rates affecting growth-focused companies, and potential competition or setbacks in technological adoption. Its global exposure and focus on leading companies like Eli Lilly and Boston Scientific provide both opportunities and risks tied to the broader health care industry trends.
GDOC Top 10 Holdings
The Goldman Sachs Future Health Care Equity ETF (GDOC) is heavily concentrated in health care technology, with Eli Lilly leading the charge thanks to its strong pipeline and market share gains. Johnson & Johnson and AstraZeneca are steady performers, bolstered by strategic product launches and growth in key markets. Meanwhile, Boston Scientific has been lagging, facing valuation concerns despite raised guidance. The fund’s global exposure adds diversification, but its focus on innovative health care names means performance hinges on the success of cutting-edge advancements in biotech and medical devices.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 11.72% | $2.57M | $988.98B | 24.55% | 71 Outperform | |
| Boston Scientific | 6.90% | $1.51M | $146.79B | 8.51% | 79 Outperform | |
| Johnson & Johnson | 6.19% | $1.36M | $494.92B | 36.46% | 78 Outperform | |
| Thermo Fisher | 5.54% | $1.21M | $218.05B | 9.75% | 73 Outperform | |
| AstraZeneca | 5.47% | $1.20M | £213.94B | 30.67% | 78 Outperform | |
| Intuitive Surgical | 4.94% | $1.08M | $201.25B | 3.59% | 78 Outperform | |
| Abbott Laboratories | 4.58% | $1.00M | $219.65B | 8.04% | 78 Outperform | |
| Argenx Se | 4.27% | $934.71K | $56.11B | 47.50% | 79 Outperform | |
| Insulet | 3.64% | $797.50K | $21.74B | 14.24% | 74 Outperform | |
| Guardant Health | 3.51% | $768.53K | $13.44B | 178.04% | 58 Neutral |
GDOC Technical Analysis
Positive
―
Price Trends
34.52
Positive
33.20
Positive
32.43
Positive
Market Momentum
0.61
Positive
59.78
Neutral
43.68
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GDOC, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 36.11, equal to the 50-day MA of 34.52, and equal to the 200-day MA of 32.43, indicating a bullish trend. The MACD of 0.61 indicates Positive momentum. The RSI at 59.78 is Neutral, neither overbought nor oversold. The STOCH value of 43.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GDOC.
GDOC Peer Comparison
Comparison Results
Performance Comparison
GDOC
Goldman Sachs Future Health Care Equity ETF
36.37
2.42
7.13%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
LGHT
Langar Global HealthTech ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents